title: Clinical characteristics of responders to interferon therapy for relapsing MS.
abstract: OBJECTIVE
  To determine the proportion of patients with multiple sclerosis (MS) who respond to interferon-beta (IFNB) therapy and assess whether clinical characteristics differ in IFNB responders vs nonresponders.
  
  
  METHODS
  Data on all patients who received IFNB who were entered in the prospective European Database for Multiple Sclerosis (EDMUS) database in Lyon as of March 31, 2001, were reviewed. Responders were defined as having a lower relapse rate on IFNB compared with the year or 2 years prior to IFNB therapy.
  
  
  RESULTS
  Two hundred sixty-two patients with relapsing MS received at least 6 months of IFNB: 200 relapsing remitting (RR) and 62 relapsing secondary progressive (SP). One-third of patients experienced a higher or identical annual relapse rate while on IFNB treatment. Compared with nonresponders, responders were older and had longer disease duration at the time IFNB was initiated. RRMS responders also had a higher relapse rate during the year prior to IFNB therapy and SPMS responders had a higher Disability Status Scale score at initiation of IFNB.
  
  
  CONCLUSIONS
  Clinical profiles of patients with relapsing MS who respond to IFNB may differ from those who do not with a more inflammatory and less neurodegenerative disease at the time IFNB is initiated.
authors.affiliation: UCSF MS Center, San Francisco, CA 94117, USA. waubant@itsa.ucsf.edu
authors.forename: E
authors.initials: E
authors.lastname: Waubant
authors.forename: S
authors.initials: S
authors.lastname: Vukusic
authors.forename: L
authors.initials: L
authors.lastname: Gignoux
authors.forename: F Durand
authors.initials: FD
authors.lastname: Dubief
authors.forename: I
authors.initials: I
authors.lastname: Achiti
authors.forename: S
authors.initials: S
authors.lastname: Blanc
authors.forename: C
authors.initials: C
authors.lastname: Renoux
authors.forename: C
authors.initials: C
authors.lastname: Confavreux
mesh_terms: D000328:Adult; D017668:Age of Onset; D016208:Databases, Factual; D005260:Female; D005602:France / Q000453:epidemiology; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D000068556:Interferon beta-1a; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000627:therapeutic use*; D008297:Male; D020528:Multiple Sclerosis, Chronic Progressive / Q000188:drug therapy* / Q000453:epidemiology; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy* / Q000453:epidemiology; D011446:Prospective Studies; D012074:Remission Induction; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D007155:Immunologic Factors; D000068576:Interferon beta-1b; D016899:Interferon-beta; D000068556:Interferon beta-1a